Brise Pharmaceuticals disclosed a licensing agreement with AbbVie covering two preclinical migraine programs, with potential payments of up to $757 million. The companies signed the deal in 2024 but have only announced it publicly this week. Under the terms, Brise is responsible for discovery while AbbVie leads global development and commercialization. Brise said it has already achieved several near-term milestones, and the agreement includes development, regulatory, commercial and sales milestones, with no upfront payment disclosed. Brise’s most advanced asset referenced in the disclosure is BR005, an oral small molecule in Phase II/III clinical trials for acute migraine. The partnership adds major Big Pharma validation to Brise’s migraine platform and reinforces AbbVie’s investment focus in neurology.